



Clinical trial results:

Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab

- Capecitabine/FUFA plus Bevacizumab versus Capecitabine/FUFA plus Irinotecan plus Bevacizumab as first-line therapy in metastatic colorectal cancer -

Summary

EudraCT number	2009-013099-38
Trial protocol	DE
Global end of trial date	16 September 2020

Results information

Result version number	v1 (current)
This version publication date	29 September 2021
First version publication date	29 September 2021
Summary attachment (see zip file)	Final Report ACCORDING TO § 42B (2) German Drug Law (AB_ML22011_2021_07_01.pdf)

Trial information

Trial identification

Sponsor protocol code	ML22011
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Klinikum der Universität München - Grosshadern
Sponsor organisation address	Marchioninistraße 15, München, Germany, 81377
Public contact	Medizinische Klinik III AG Onkologie, Klinikum der Universität München - Grosshadern, +49 89 4400 0, onkologiestudien@med.uni-muenchen.de
Scientific contact	Medizinische Klinik III AG Onkologie, Klinikum der Universität München - Grosshadern, +49 89 4400 0, onkologiestudien@med.uni-muenchen.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 January 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 September 2020
Global end of trial reached?	Yes
Global end of trial date	16 September 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Evaluation of effectiveness in correlation to tolerability of both therapy schemes in patients with metastatic colorectal cancer without Prior therapy.

Protection of trial subjects:

The present study was developed for those patients, who do not necessarily require treatment with primary combination chemotherapy according to the recommendations of the S3 guideline (Group 3, Schmiegel 2008). Patients with multiple metastases that are not primarily resectable and for whom the option for resection after the metastases have regressed is unlikely. The patients should be in a good general state of health (ECOG 0-1) and exhibit an oligo- or asymptomatic disease (group 3 according to the S3 guideline).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 December 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	36 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 434
Worldwide total number of subjects	434
EEA total number of subjects	434

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	293
From 65 to 84 years	138
85 years and over	3

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Investigating an optimal first-line treatment, the current study compares a sequential escalation strategy starting with FP 1 Bev plus the addition of Iri at disease progression with initial use of the three-drug regimen (FP 1 Iri 1 Bev).

Pre-assignment period milestones

Number of subjects started	434
----------------------------	-----

Number of subjects completed	421
------------------------------	-----

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Protocol deviation: 1
----------------------------	-----------------------

Reason: Number of subjects	Terminated study before treatment start: 12
----------------------------	---

Period 1

Period 1 title	Overall Trial (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Not blinded
---------------	-------------

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Capecitabine plus bevacizumab
-----------	-------------------------------

Arm description:

Capecitabine: 2 x 1,250 mg/m² Day 1-14 followed by a 1 week break

Bevacizumab: 7.5 mg/kg Day 1

The regimen is repeated at 3-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Capecitabine
--	--------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Oral suspension
----------------------	-----------------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Capecitabine: 2 x 1,250 mg/m² Day 1-14 followed by a 1 week break

Investigational medicinal product name	Bevacizumab
--	-------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Infusion
----------------------	----------

Routes of administration	Infusion
--------------------------	----------

Dosage and administration details:

Bevacizumab: 7.5 mg/kg Day 1

Arm title	5-FUFA plus bevacizumab
-----------	-------------------------

Arm description:

Folinic acid (racemic) 400 mg/m² IV, 120 min Day 1
 5-FU 400 mg/m² bolus Day 1
 5-FU 2,400 mg/m² IV for 46 h Day 1-2
 Bevacizumab: 5.0 mg/kg Day 1
 The regimen is repeated at 2-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab

Arm type	Active comparator
Investigational medicinal product name	5-FU bolus
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Injection
Dosage and administration details:	
5-FU 400 mg/m ² bolus	Day 1
Investigational medicinal product name	5-FU
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Infusion
Dosage and administration details:	
5-FU 2,400 mg/m ² IV for 46 h	Day 1-2
Investigational medicinal product name	Folinic acid (racemic)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Infusion
Dosage and administration details:	
Folinic acid (racemic) 400 mg/m ² IV, 120 min	Day 1
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Infusion
Dosage and administration details:	
Bevacizumab: 5.0 mg/kg	Day 1

Number of subjects in period 1^[1]	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab
Started	212	209
Completed	212	209

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Transmitted numbers of subjects are correct.

Baseline characteristics

Reporting groups

Reporting group title	Capecitabine plus bevacizumab
-----------------------	-------------------------------

Reporting group description:

Capecitabine: 2 x 1,250 mg/m² Day 1-14 followed by a 1 week break

Bevacizumab: 7.5 mg/kg Day 1

The regimen is repeated at 3-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab.

Reporting group title	5-FUFA plus bevacizumab
-----------------------	-------------------------

Reporting group description:

Folinic acid (racemic) 400 mg/m² IV, 120 min Day 1

5-FU 400 mg/m² bolus Day 1

5-FU 2,400 mg/m² IV for 46 h Day 1-2

Bevacizumab: 5.0 mg/kg Day 1

The regimen is repeated at 2-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab

Reporting group values	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab	Total
Number of subjects	212	209	421
Age categorical			
Units: Subjects			
Adults (18-64 years)	151	132	283
From 65-84 years	60	75	135
85 years and over	1	2	3
Age continuous			
Units: years			
median	71	69	
full range (min-max)	43 to 87	42 to 88	-
Gender categorical			
Units: Subjects			
Female	137	144	281
Male	75	65	140
ECOG Performance status			
Units: Subjects			
ECOG 0	127	124	251
ECOG 1	85	83	168
unkown	0	2	2
Onset of metastases			
Units: Subjects			
Synchronous	151	145	296
Metachronous	57	59	116
Unknown	4	5	9
Site of primary tumor			
Units: Subjects			
Left (splenic flexurirectum)	140	138	278

Right (transverse coloncecum)	68	64	132
Unknown	4	7	11
No. of metastatic sites			
Units: Subjects			
1 Metastase	74	75	149
>= 2 Metastases	133	126	259
unkown	5	8	13
Fluoropyrimidine used			
Units: Subjects			
Capecitabine	151	136	287
Infusional fluorouracil	61	73	134

End points

End points reporting groups

Reporting group title	Capecitabine plus bevacizumab
Reporting group description:	
Capecitabine: 2 x 1,250 mg/m ² Day 1-14 followed by a 1 week break	
Bevacizumab: 7.5 mg/kg Day 1	
The regimen is repeated at 3-week intervals	
Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab.	
Reporting group title	5-FUFA plus bevacizumab
Reporting group description:	
Folinic acid (racemic) 400 mg/m ² IV, 120 min Day 1	
5-FU 400 mg/m ² bolus Day 1	
5-FU 2,400 mg/m ² IV for 46 h Day 1-2	
Bevacizumab: 5.0 mg/kg Day 1	
The regimen is repeated at 2-week intervals	
Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab	

Primary: Time to failure of strategy

End point title	Time to failure of strategy
End point description:	
<ul style="list-style-type: none">Time to failure of treatment strategy (TFS) will be determined as the primary endpoint. In the control arm, this corresponds to the time from randomisation to definitive progression under XELIRI/FOLFIRI + bevacizumab (PFS-1) (allowing for the possible resumption after initial response, pause of therapy and subsequent progression). In the experimental arm, an escalation to the combination XELIRI or FOLFIRI + bevacizumab can take place, if capecitabine/FUFA + bevacizumab fails (PFS-1). Failure of this treatment strategy is defined as second progression (PFS-2).If a comparable TFS is achieved in both treatment arms, a side effect analysis will be used to help in defining the better treatment strategy. Treatment-associated toxicity will be evaluated as analysis of all grade 2-5 toxicities (according to NCI CTCAE, Version 4.0) divided by the number of treatment cycles administered during the total TFS period.	
End point type	Primary
End point timeframe:	
the time from randomisation to definitive progression under XELIRI/FOLFIRI + bevacizumab (PFS-1) . In the experimental arm, an escalation to the combination XELIRI or FOLFIRI + bevacizumab can take place, if capecitabine/FUFA + bevacizumab fails (PFS-1)	

End point values	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	194	186		
Units: months				
median (confidence interval 90%)	9.6 (8.6 to 10.6)	9.9 (8.8 to 10.6)		

Attachments (see zip file)	Kaplan-Meier-TFS/TFS ML22011.png
-----------------------------------	----------------------------------

Statistical analyses

Statistical analysis title	TFS
Comparison groups	Capecitabine plus bevacizumab v 5-FUFA plus bevacizumab
Number of subjects included in analysis	380
Analysis specification	Post-hoc
Analysis type	equivalence
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.73
upper limit	1.02
Variability estimate	Standard deviation

Secondary: Response Data

End point title	Response Data
End point description:	
End point type	Secondary
End point timeframe:	<ul style="list-style-type: none"> Overall survival (OS) in both treatment arms, including 60-day mortality PFS-1 (progression-free survival) in both treatment arms (decentralised recording by study sites)

End point values	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	212	209		
Units: months				
median (confidence interval 95%)				
OS	21.9 (20.2 to 25.0)	23.5 (20.9 to 27.9)		
PFS-1	8.0 (6.9 to 9.9)	9.9 (8.7 to 10.9)		

Statistical analyses

Statistical analysis title	Overall Response Rate - ORR
Comparison groups	Capecitabine plus bevacizumab v 5-FUFA plus bevacizumab
Number of subjects included in analysis	421
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.005
Method	Logrank
Parameter estimate	Odds ratio (OR)
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	0.74
Variability estimate	Standard deviation

Statistical analysis title	Progression Free Survival - PFS1
Comparison groups	Capecitabine plus bevacizumab v 5-FUFA plus bevacizumab
Number of subjects included in analysis	421
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	< 0.001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	0.85
Variability estimate	Standard deviation

Statistical analysis title	Overall Survival - OS
Comparison groups	Capecitabine plus bevacizumab v 5-FUFA plus bevacizumab

Number of subjects included in analysis	421
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.14
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.06
Variability estimate	Standard deviation

Secondary: objective response rate (ORR)

End point title	objective response rate (ORR)
End point description:	
End point type	Secondary
End point timeframe:	
• Response rate (ORR) (decentralised recording by study sites)	

End point values	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	212	209		
Units: subjects				
CR/PR	80	117		

Statistical analyses

Statistical analysis title	Objective Response Rate - ORR
Comparison groups	5-FUFA plus bevacizumab v Capecitabine plus bevacizumab
Number of subjects included in analysis	421
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.0002
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	0.477

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.323
upper limit	0.704
Variability estimate	Standard deviation

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events include all events that occur in a patient / participant in a clinical study following administration of a medicinal product. A causal association with this treatment is not a requirement here.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.1

Reporting groups

Reporting group title	Capecitabine plus bevacizumab
-----------------------	-------------------------------

Reporting group description:

Capecitabine: 2 x 1,250 mg/m² Day 1-14 followed by a 1 week break

Bevacizumab: 7.5 mg/kg Day 1

The regimen is repeated at 3-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab.

Reporting group title	5-FUFA plus bevacizumab
-----------------------	-------------------------

Reporting group description:

Folinic acid (racemic) 400 mg/m² IV, 120 min Day 1

5-FU 400 mg/m² bolus Day 1

5-FU 2,400 mg/m² IV for 46 h Day 1-2

Bevacizumab: 5.0 mg/kg Day 1

The regimen is repeated at 2-week intervals

Treatment will be continued until progression or toxicity. If progression occurs, the scheme will be escalated: from capecitabine plus bevacizumab to XELIRI plus bevacizumab or from FUFA plus bevacizumab to FOLFIRI and bevacizumab

Serious adverse events	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 212 (13.68%)	68 / 210 (32.38%)	
number of deaths (all causes)	3	4	
number of deaths resulting from adverse events	1	3	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	8 / 212 (3.77%)	4 / 210 (1.90%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiccups			

subjects affected / exposed	2 / 212 (0.94%)	4 / 210 (1.90%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	3 / 212 (1.42%)	6 / 210 (2.86%)	
occurrences causally related to treatment / all	0 / 81	2 / 103	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
other			
subjects affected / exposed	6 / 212 (2.83%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 37	0 / 25	
deaths causally related to treatment / all	0 / 2	0 / 0	
Respiratory distress			
subjects affected / exposed	2 / 212 (0.94%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vomiting			
subjects affected / exposed	4 / 212 (1.89%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	1 / 35	2 / 53	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound healing complications			

subjects affected / exposed	5 / 212 (2.36%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Chills			
subjects affected / exposed	5 / 212 (2.36%)	6 / 210 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	4 / 212 (1.89%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	20 / 212 (9.43%)	19 / 210 (9.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fever			
subjects affected / exposed	24 / 212 (11.32%)	38 / 210 (18.10%)	
occurrences causally related to treatment / all	0 / 3	4 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	10 / 212 (4.72%)	17 / 210 (8.10%)	
occurrences causally related to treatment / all	1 / 6	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hand-Foot-Syndrome			
subjects affected / exposed	26 / 212 (12.26%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 100	0 / 61	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucositis/Stomatitis			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 64	1 / 50	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			

Sudden death			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Fall			
subjects affected / exposed	5 / 212 (2.36%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Withdrawal syndrome			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Enterocoele			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device dislocation			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device implantation			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural site reaction			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	7 / 212 (3.30%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	3 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	4 / 212 (1.89%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac toxicity			
subjects affected / exposed	13 / 212 (6.13%)	11 / 210 (5.24%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardial-ischemic event			
subjects affected / exposed	3 / 212 (1.42%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Cardiovascular disorder			
subjects affected / exposed	2 / 212 (0.94%)	4 / 210 (1.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	4 / 212 (1.89%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	2 / 212 (0.94%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 137	1 / 135	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	2 / 212 (0.94%)	7 / 210 (3.33%)	
occurrences causally related to treatment / all	0 / 0	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 32	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	3 / 212 (1.42%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	2 / 212 (0.94%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 128	0 / 123	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			

subjects affected / exposed	27 / 212 (12.74%)	18 / 210 (8.57%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological disorder			
subjects affected / exposed	5 / 212 (2.36%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	10 / 212 (4.72%)	9 / 210 (4.29%)	
occurrences causally related to treatment / all	0 / 125	0 / 121	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	4 / 212 (1.89%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Abscesses fistulae			
subjects affected / exposed	7 / 212 (3.30%)	7 / 210 (3.33%)	
occurrences causally related to treatment / all	1 / 5	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal haemorrhage			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ascites			
subjects affected / exposed	3 / 212 (1.42%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding/hemorrhage			
subjects affected / exposed	6 / 212 (2.83%)	3 / 210 (1.43%)	
occurrences causally related to treatment / all	0 / 44	1 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bicarbonate decreased			

subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 31	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	2 / 212 (0.94%)	11 / 210 (5.24%)	
occurrences causally related to treatment / all	0 / 0	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematologic toxicity			
subjects affected / exposed	5 / 212 (2.36%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 147	0 / 161	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatologic toxicity			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 128	0 / 123	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	5 / 212 (2.36%)	4 / 210 (1.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	26 / 212 (12.26%)	23 / 210 (10.95%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PCO2 decreased			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PO2 decreased			

subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboembolic event			
subjects affected / exposed	18 / 212 (8.49%)	21 / 210 (10.00%)	
occurrences causally related to treatment / all	5 / 37	4 / 33	
deaths causally related to treatment / all	0 / 1	0 / 1	
Thrombosis (any)			
subjects affected / exposed	5 / 212 (2.36%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Cholangitis			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			

subjects affected / exposed	28 / 212 (13.21%)	46 / 210 (21.90%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	21 / 212 (9.91%)	17 / 210 (8.10%)	
occurrences causally related to treatment / all	1 / 111	5 / 124	
deaths causally related to treatment / all	0 / 2	0 / 0	
GI perforation			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	2 / 212 (0.94%)	2 / 210 (0.95%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	10 / 212 (4.72%)	8 / 210 (3.81%)	
occurrences causally related to treatment / all	1 / 10	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Intestinal ischaemia			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Skin reaction			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 58	1 / 59	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Calculus ureteric			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	1 / 212 (0.47%)	4 / 210 (1.90%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal disorder			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	2 / 212 (0.94%)	5 / 210 (2.38%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Urinary retention			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract disorder			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Febrile infection			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			

subjects affected / exposed	14 / 212 (6.60%)	16 / 210 (7.62%)	
occurrences causally related to treatment / all	1 / 102	1 / 102	
deaths causally related to treatment / all	0 / 1	0 / 1	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Capecitabine plus bevacizumab	5-FUFA plus bevacizumab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	212 / 212 (100.00%)	210 / 210 (100.00%)	
Surgical and medical procedures			
Anastomotic complication			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Catheter site ulcer			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Ageusia			
subjects affected / exposed	2 / 212 (0.94%)	4 / 210 (1.90%)	
occurrences (all)	2	4	
Allergy			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences (all)	1	2	
Alopecia			
subjects affected / exposed	52 / 212 (24.53%)	89 / 210 (42.38%)	
occurrences (all)	52	89	
Anxiety			
subjects affected / exposed	2 / 212 (0.94%)	3 / 210 (1.43%)	
occurrences (all)	2	3	
Bronchospasm			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Cachexia			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences (all)	1	1	

Chest discomfort		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	0
Death/Sudden death		
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)
occurrences (all)	2	0
Decreased appetite		
subjects affected / exposed	34 / 212 (16.04%)	43 / 210 (20.48%)
occurrences (all)	34	43
Dehydration		
subjects affected / exposed	2 / 212 (0.94%)	11 / 210 (5.24%)
occurrences (all)	2	11
Dizziness		
subjects affected / exposed	32 / 212 (15.09%)	26 / 210 (12.38%)
occurrences (all)	32	26
Dry mouth		
subjects affected / exposed	5 / 212 (2.36%)	7 / 210 (3.33%)
occurrences (all)	5	7
Dysgeusia		
subjects affected / exposed	20 / 212 (9.43%)	13 / 210 (6.19%)
occurrences (all)	20	13
Dyspepsia		
subjects affected / exposed	9 / 212 (4.25%)	9 / 210 (4.29%)
occurrences (all)	9	9
Dysphagia		
subjects affected / exposed	4 / 212 (1.89%)	5 / 210 (2.38%)
occurrences (all)	4	5
Dysphonia		
subjects affected / exposed	18 / 212 (8.49%)	8 / 210 (3.81%)
occurrences (all)	18	8
Dyspnoea		
subjects affected / exposed	20 / 212 (9.43%)	19 / 210 (9.05%)
occurrences (all)	20	19
Dyspnoea exertional		
subjects affected / exposed	5 / 212 (2.36%)	5 / 210 (2.38%)
occurrences (all)	5	5

Dysuria		
subjects affected / exposed	1 / 212 (0.47%)	4 / 210 (1.90%)
occurrences (all)	1	4
Eating disorder		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Enterocoele		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Eructation		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Extravasation		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Faecal incontinence		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Faecaloma		
subjects affected / exposed	1 / 212 (0.47%)	4 / 210 (1.90%)
occurrences (all)	1	4
Faeces discoloured		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Fatigue		
subjects affected / exposed	8 / 212 (3.77%)	4 / 210 (1.90%)
occurrences (all)	8	4
Feeling cold		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Fistula		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Flatulence		
subjects affected / exposed	2 / 212 (0.94%)	2 / 210 (0.95%)
occurrences (all)	2	2

Flushing		
subjects affected / exposed	1 / 212 (0.47%)	3 / 210 (1.43%)
occurrences (all)	1	3
Frequent bowel movements		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Gait disturbance		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
General physical health deterioration		
subjects affected / exposed	1 / 212 (0.47%)	17 / 210 (8.10%)
occurrences (all)	1	17
Haemorrhoids		
subjects affected / exposed	4 / 212 (1.89%)	3 / 210 (1.43%)
occurrences (all)	4	3
Hallucination		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Hand-foot syndrome		
subjects affected / exposed	100 / 212 (47.17%)	61 / 210 (29.05%)
occurrences (all)	100	61
Hernia		
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)
occurrences (all)	2	0
Hiccups		
subjects affected / exposed	2 / 212 (0.94%)	4 / 210 (1.90%)
occurrences (all)	2	4
Hot flush		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Hyperaesthesia		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Hypercalcaemia		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0

Hyperglycaemia		
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)
occurrences (all)	1	2
Hyperhidrosis		
subjects affected / exposed	1 / 212 (0.47%)	6 / 210 (2.86%)
occurrences (all)	1	6
Hyperkalaemia		
subjects affected / exposed	3 / 212 (1.42%)	4 / 210 (1.90%)
occurrences (all)	3	4
Hypertension		
subjects affected / exposed	137 / 212 (64.62%)	135 / 210 (64.29%)
occurrences (all)	137	135
Hyperuricemia		
subjects affected / exposed	24 / 212 (11.32%)	25 / 210 (11.90%)
occurrences (all)	24	25
Hypoaesthesia		
subjects affected / exposed	7 / 212 (3.30%)	9 / 210 (4.29%)
occurrences (all)	7	9
Hypoalbuminaemia		
subjects affected / exposed	2 / 212 (0.94%)	6 / 210 (2.86%)
occurrences (all)	2	6
Hypocalcaemia		
subjects affected / exposed	7 / 212 (3.30%)	9 / 210 (4.29%)
occurrences (all)	7	9
Hypomagnesaemia		
subjects affected / exposed	3 / 212 (1.42%)	1 / 210 (0.48%)
occurrences (all)	3	1
Hyponatraemia		
subjects affected / exposed	5 / 212 (2.36%)	4 / 210 (1.90%)
occurrences (all)	5	4
Hypotension		
subjects affected / exposed	4 / 212 (1.89%)	4 / 210 (1.90%)
occurrences (all)	4	4
Icterus		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0

Ileus		
subjects affected / exposed	10 / 212 (4.72%)	8 / 210 (3.81%)
occurrences (all)	10	8
Incisional hernia		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Increased bronchial secretion		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Inguinal hernia		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Initial insomnia		
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)
occurrences (all)	1	2
International normalised ratio increased		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Intestinal ischaemia		
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)
occurrences (all)	2	0
Joint swelling		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Laceration		
subjects affected / exposed	0 / 212 (0.00%)	3 / 210 (1.43%)
occurrences (all)	0	3
Lacrimation increased		
subjects affected / exposed	4 / 212 (1.89%)	0 / 210 (0.00%)
occurrences (all)	4	0
Lipase decreased		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Lipase increased		

subjects affected / exposed	2 / 212 (0.94%)	2 / 210 (0.95%)
occurrences (all)	2	2
Malaise		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Memory impairment		
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)
occurrences (all)	0	2
Mental disorder		
subjects affected / exposed	128 / 212 (60.38%)	123 / 210 (58.57%)
occurrences (all)	128	123
Microangiopathy		
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)
occurrences (all)	0	2
Mucosal dryness		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Mucositis/Stomatitis		
subjects affected / exposed	64 / 212 (30.19%)	50 / 210 (23.81%)
occurrences (all)	64	50
Muscle spasms		
subjects affected / exposed	5 / 212 (2.36%)	6 / 210 (2.86%)
occurrences (all)	5	6
Muscular weakness		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Myopathy		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Myosclerosis		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Nail changes/Paronychia		
subjects affected / exposed	6 / 212 (2.83%)	11 / 210 (5.24%)
occurrences (all)	6	11
Nasal congestion		

subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Nasal discomfort		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Nasal dryness		
subjects affected / exposed	1 / 212 (0.47%)	6 / 210 (2.86%)
occurrences (all)	1	6
Nasal inflammation		
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)
occurrences (all)	2	1
Nausea		
subjects affected / exposed	81 / 212 (38.21%)	103 / 210 (49.05%)
occurrences (all)	81	103
Neutropenic sepsis		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Night sweats		
subjects affected / exposed	2 / 212 (0.94%)	7 / 210 (3.33%)
occurrences (all)	2	7
Odynophagia		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Onycholysis		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Onychoclasia		
subjects affected / exposed	7 / 212 (3.30%)	5 / 210 (2.38%)
occurrences (all)	7	5
Onychomadesis		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Onychomycosis		
subjects affected / exposed	2 / 212 (0.94%)	3 / 210 (1.43%)
occurrences (all)	2	3
Osteonecrosis		

subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Other		
subjects affected / exposed	37 / 212 (17.45%)	25 / 210 (11.90%)
occurrences (all)	37	25
PCO2 decreased		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
PO2 decreased		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Pain		
subjects affected / exposed	125 / 212 (58.96%)	121 / 210 (57.62%)
occurrences (all)	125	121
Palpitations		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Performance status decreased		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Pleural effusion		
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)
occurrences (all)	2	1
Pleurisy		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Pollakiuria		
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)
occurrences (all)	0	2
Procedural site reaction		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Productive cough		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Prothrombin time prolonged		

subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)
occurrences (all)	2	1
Respiratory distress		
subjects affected / exposed	3 / 212 (1.42%)	2 / 210 (0.95%)
occurrences (all)	3	2
Rhinorrhoea		
subjects affected / exposed	3 / 212 (1.42%)	2 / 210 (0.95%)
occurrences (all)	3	2
Salivary hypersecretion		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Sjogren's syndrome		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Sleep apnoea syndrome		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Subileus		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Syncope		
subjects affected / exposed	2 / 212 (0.94%)	7 / 210 (3.33%)
occurrences (all)	2	7
Thirst		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Throat tightness		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Thyroid-dysregulation		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Tooth extraction		
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)
occurrences (all)	2	0
Varicose vein		

subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	3 / 210 (1.43%) 3	
Vertigo subjects affected / exposed occurrences (all)	4 / 212 (1.89%) 4	1 / 210 (0.48%) 1	
Vomiting subjects affected / exposed occurrences (all)	35 / 212 (16.51%) 35	53 / 210 (25.24%) 53	
Weight decreased subjects affected / exposed occurrences (all)	21 / 212 (9.91%) 21	25 / 210 (11.90%) 25	
Weight increased subjects affected / exposed occurrences (all)	3 / 212 (1.42%) 3	6 / 210 (2.86%) 6	
Withdrawal syndrome subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Immune system disorders Arthritis subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	1 / 210 (0.48%) 1	
Chills subjects affected / exposed occurrences (all)	5 / 212 (2.36%) 5	6 / 210 (2.86%) 6	
Product issues Device dislocation subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Device related infection subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Infusional-related allergic reaction subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	2 / 210 (0.95%) 2	
Medical device implantation			

subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Overdose			
subjects affected / exposed	1 / 212 (0.47%)	3 / 210 (1.43%)	
occurrences (all)	1	3	
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Contusion			
subjects affected / exposed	3 / 212 (1.42%)	0 / 210 (0.00%)	
occurrences (all)	3	0	
Fall			
subjects affected / exposed	5 / 212 (2.36%)	3 / 210 (1.43%)	
occurrences (all)	5	3	
Femoral neck fracture			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Haematoma			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Hand fracture			
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)	
occurrences (all)	0	2	
Rib fracture			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Sepsis			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences (all)	1	2	
Wound			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences (all)	1	2	
Wound healing complications			

subjects affected / exposed occurrences (all)	5 / 212 (2.36%) 5	5 / 210 (2.38%) 5	
Congenital, familial and genetic disorders			
Erectile dysfunction			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	7 / 212 (3.30%)	2 / 210 (0.95%)	
occurrences (all)	7	2	
Blood pressure increased			
subjects affected / exposed	4 / 212 (1.89%)	1 / 210 (0.48%)	
occurrences (all)	4	1	
Cardiac disorder			
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)	
occurrences (all)	2	1	
Cardiac failure			
subjects affected / exposed	1 / 212 (0.47%)	2 / 210 (0.95%)	
occurrences (all)	1	2	
Cardiac toxicity			
subjects affected / exposed	13 / 212 (6.13%)	11 / 210 (5.24%)	
occurrences (all)	13	11	
Cardial-ischemic event			
subjects affected / exposed	3 / 212 (1.42%)	0 / 210 (0.00%)	
occurrences (all)	3	0	
Cardiomyopathy			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Cardiovascular disorder			
subjects affected / exposed	2 / 212 (0.94%)	4 / 210 (1.90%)	
occurrences (all)	2	4	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Circulatory collapse			

subjects affected / exposed occurrences (all)	4 / 212 (1.89%) 4	2 / 210 (0.95%) 2	
Tachycardia subjects affected / exposed occurrences (all)	5 / 212 (2.36%) 5	3 / 210 (1.43%) 3	
Nervous system disorders			
Ataxia subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Cholinergic syndrome subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Convulsion subjects affected / exposed occurrences (all)	3 / 212 (1.42%) 3	0 / 210 (0.00%) 0	
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	4 / 210 (1.90%) 4	
Nervous system disorder subjects affected / exposed occurrences (all)	27 / 212 (12.74%) 27	18 / 210 (8.57%) 18	
Neurological disorder subjects affected / exposed occurrences (all)	5 / 212 (2.36%) 5	3 / 210 (1.43%) 3	
PNP subjects affected / exposed occurrences (all)	27 / 212 (12.74%) 27	18 / 210 (8.57%) 18	
Tremor subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	2 / 210 (0.95%) 2	
Blood and lymphatic system disorders			
Abscess limb subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Abscesses fistulae			

subjects affected / exposed	7 / 212 (3.30%)	7 / 210 (3.33%)
occurrences (all)	7	7
Activated partial thromboplastin time prolonged		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Activated partial thromboplastin time shortened		
subjects affected / exposed	16 / 212 (7.55%)	13 / 210 (6.19%)
occurrences (all)	16	13
Ascites		
subjects affected / exposed	3 / 212 (1.42%)	1 / 210 (0.48%)
occurrences (all)	3	1
Bleeding/hemorrhage		
subjects affected / exposed	2 / 212 (0.94%)	6 / 210 (2.86%)
occurrences (all)	2	6
Blood albumin decreased		
subjects affected / exposed	2 / 212 (0.94%)	6 / 210 (2.86%)
occurrences (all)	2	6
Blood bicarbonate decreased		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Blood creatinine decreased		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Blood creatinine increased		
subjects affected / exposed	31 / 212 (14.62%)	27 / 210 (12.86%)
occurrences (all)	31	27
Blood glucose increased		
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)
occurrences (all)	2	1
Blood thyroid stimulating hormone increased		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Blood uric acid increased		

subjects affected / exposed	5 / 212 (2.36%)	5 / 210 (2.38%)
occurrences (all)	5	5
Blood urine present		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Coagulation time prolonged		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Electrolyte imbalance		
subjects affected / exposed	27 / 212 (12.74%)	27 / 210 (12.86%)
occurrences (all)	27	27
Febrile neutropenia		
subjects affected / exposed	3 / 212 (1.42%)	3 / 210 (1.43%)
occurrences (all)	3	3
Haematologic toxicity		
subjects affected / exposed	147 / 212 (69.34%)	161 / 210 (76.67%)
occurrences (all)	147	161
Hyperalbuminaemia		
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)
occurrences (all)	0	1
Iron deficiency		
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)
occurrences (all)	1	1
Leukocytosis		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Leukopenia		
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)
occurrences (all)	0	2
Lymphopenia		
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)
occurrences (all)	1	0
Neutropenia		
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)
occurrences (all)	0	2
Oedema		

subjects affected / exposed	26 / 212 (12.26%)	23 / 210 (10.95%)	
occurrences (all)	26	23	
Protein total decreased			
subjects affected / exposed	6 / 212 (2.83%)	8 / 210 (3.81%)	
occurrences (all)	6	8	
Proteinuria			
subjects affected / exposed	8 / 212 (3.77%)	10 / 210 (4.76%)	
occurrences (all)	8	10	
Thrombocytopenia			
subjects affected / exposed	2 / 212 (0.94%)	1 / 210 (0.48%)	
occurrences (all)	2	1	
Thromboembolic event			
subjects affected / exposed	37 / 212 (17.45%)	33 / 210 (15.71%)	
occurrences (all)	37	33	
Thrombosis (any)			
subjects affected / exposed	5 / 212 (2.36%)	5 / 210 (2.38%)	
occurrences (all)	5	5	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 212 (0.00%)	2 / 210 (0.95%)	
occurrences (all)	0	2	
Chromatopsia			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Eye irritation			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Ocular hyperaemia			
subjects affected / exposed	2 / 212 (0.94%)	0 / 210 (0.00%)	
occurrences (all)	2	0	
Photophobia			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Retinal detachment			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences (all)	1	1	

Vision blurred subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	1 / 210 (0.48%) 1	
Visual impairment subjects affected / exposed occurrences (all)	5 / 212 (2.36%) 5	1 / 210 (0.48%) 1	
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	3 / 212 (1.42%) 3	10 / 210 (4.76%) 10	
Abdominal hernia subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Anal haemorrhage subjects affected / exposed occurrences (all)	2 / 212 (0.94%) 2	0 / 210 (0.00%) 0	
Anorectal discomfort subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Cholangitis subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Cholelithiasis subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Cholestasis subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	2 / 210 (0.95%) 2	
Constipation subjects affected / exposed occurrences (all)	28 / 212 (13.21%) 28	46 / 210 (21.90%) 46	
Diarrhoea subjects affected / exposed occurrences (all)	111 / 212 (52.36%) 111	124 / 210 (59.05%) 124	
GI perforation			

subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Gastritis			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences (all)	1	1	
Gastrointestinal disorder			
subjects affected / exposed	2 / 212 (0.94%)	2 / 210 (0.95%)	
occurrences (all)	2	2	
Gastrointestinal perforation			
subjects affected / exposed	0 / 212 (0.00%)	1 / 210 (0.48%)	
occurrences (all)	0	1	
Gastrointestinal ulcer			
subjects affected / exposed	1 / 212 (0.47%)	1 / 210 (0.48%)	
occurrences (all)	1	1	
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	1 / 212 (0.47%)	0 / 210 (0.00%)	
occurrences (all)	1	0	
Hepatologic toxicity			
subjects affected / exposed	128 / 212 (60.38%)	123 / 210 (58.57%)	
occurrences (all)	128	123	
Skin and subcutaneous tissue disorders			
Acneiform exanthema/Rash			
subjects affected / exposed	16 / 212 (7.55%)	13 / 210 (6.19%)	
occurrences (all)	16	13	
Skin disorder			
subjects affected / exposed	5 / 212 (2.36%)	3 / 210 (1.43%)	
occurrences (all)	5	3	
Skin reaction			
subjects affected / exposed	58 / 212 (27.36%)	59 / 210 (28.10%)	
occurrences (all)	58	59	
Renal and urinary disorders			

Bladder discomfort subjects affected / exposed occurrences (all)	6 / 212 (2.83%) 6	5 / 210 (2.38%) 5	
Calculus ureteric subjects affected / exposed occurrences (all)	2 / 212 (0.94%) 2	0 / 210 (0.00%) 0	
Nitrite urine subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Renal disorder subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Renal failure subjects affected / exposed occurrences (all)	2 / 212 (0.94%) 2	5 / 210 (2.38%) 5	
Urinary hesitation subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	1 / 210 (0.48%) 1	
Urinary retention subjects affected / exposed occurrences (all)	0 / 212 (0.00%) 0	1 / 210 (0.48%) 1	
Urinary tract disorder subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Endocrine disorders Endocrine disorder subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	1 / 210 (0.48%) 1	
Infections and infestations Febrile infection subjects affected / exposed occurrences (all)	1 / 212 (0.47%) 1	0 / 210 (0.00%) 0	
Fever subjects affected / exposed occurrences (all)	24 / 212 (11.32%) 24	38 / 210 (18.10%) 38	
Infection			

subjects affected / exposed	102 / 212 (48.11%)	102 / 210 (48.57%)	
occurrences (all)	102	102	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 July 2010	<p>To evaluate the tumor dynamics in all study patients, it is planned that too the follow-up examinations (every 3 months for a minimum of 36 Months after randomization) a computed tomography and a RECIST-compliant one</p> <p>Assessment of this carried out according to the RECIST criteria version 1.1 become. According to this amendment, these should be mandatory until the first one is established</p> <p>definitive progression (arm A) or the second definitive progression (arm B) respectively.</p> <p>Furthermore, instead of 10ml</p> <p>EDTA blood now 10ml PAXgene blood once at the start of the study therapy (or within the first two treatment cycles). All samples</p> <p>are, as described in the existing test plan in version 2.0 from 25.08.2010, sent to the central biobank at Klinikum Großhadern.</p> <p>In addition, this amendment indicates that the</p> <p>Responsibility for the area of data management from the company "Scientific Service Pharma (WiSP) GmbH" to ClinAssess GmbH</p> <p>and that editorial changes were made throughout the test plan</p> <p>have been carried out (see also the test plan version 3.0 dated May 19, 2011 with highlighted changes).</p> <p>As part of this amendment, the study title was also modified, since the</p> <p>Existing study titles are not comprehensive and sufficiently precise</p> <p>Treatment options reflected within the study. The modified one</p> <p>According to the sequential (de) escalation options (the</p> <p>less intensive therapy arm (A) offers the possibility of escalation (after</p> <p>Progression), the more intensive therapy arm (B) offers the possibility of de-escalation</p> <p>(in the case of a stable disease state or toxicity) and can subsequently be re-escalated again</p> <p>(according to progression)) calculation.</p>
08 February 2013	<p>changes in the</p> <p>Formulation for study therapy made. It was the one so far</p> <p>existing formulation "Capecitabin" around the term "FUFA" (5-fluorouracil and Folinic acid), or the formulation "XELIRI" (capecitabine plus irinotecan) around the</p> <p>Term "FOLFIRI" (5-fluorouracil, folinic acid and irinotecan) added. A detailed</p> <p>All changes to this are not listed.</p> <p>As a result of the opening of the study to the infusional fluoropyrimidine was a</p> <p>further secondary study endpoint formulated, as well as the inclusion and</p> <p>exclusion criteria</p> <p>customized. The primary and secondary study objectives were for the better</p> <p>Understanding editorially revised but the content remains unchanged.</p> <p>Since the study with this amendment after the approval extension for</p> <p>Bevacizumab for "treatment beyond progression" will be continued as soon as it</p> <p>comes into force</p> <p>of this amendment Bevacizumab is no longer made available as study product.</p> <p>Corresponding changes were made in the test plan.</p> <p>The other changes in the test plan with regard to the translational</p> <p>Research project can be found listed in this amendment.</p> <p>In addition, this amendment indicates that responsibility for</p> <p>the field of biometrics and statistics from the company "Wissenschaftlicher Service</p> <p>Pharma</p> <p>(WiSP) GmbH "was transferred to ClinAssess GmbH.</p>

09 June 2015	<p>The present change to the study plan of the ML22011 / AIOKRK0110 study is addressed</p> <p>editorial changes, updating of side effects, adding new ones</p> <p>secondary endpoints (e.g. risk group evaluation, co-morbidity, central, pseudonymized collection and evaluation of the CT images), as well as a reduction in</p> <p>Sample size planning.</p> <p>The current design sees the non-inferiority of the "time-to-failure" as the primary endpoint.</p> <p>of-strategy "(= TFS) from ARM A to ARM B. Although the sequential</p> <p>Therapy of metastatic colorectal cancer according to the current ESMO guideline as</p> <p>Therapy option and therefore the comparison of a sequence and an up-front</p> <p>Therapy appears interesting and necessary, in our view the primary endpoint is im</p> <p>current scientific context of the study is not unproblematic, as we have already done in</p> <p>Discussed in detail at the joint ethics committee meeting in April 2015</p> <p>to have.</p> <p>After a detailed (including statistical) consultation with you, we will apply for this</p> <p>Amendments propose a reduction in power from 80% to 70%: This means a</p> <p>Case number reduction from 506 evaluable patients to 378 evaluable patients and thus</p> <p>an estimated total enrollment of 420-450 patients, depending on the proportion of evaluable patients. This goal is at an average recruitment of 7-8</p> <p>Patients per month and a number of patients of 396 (as of June 8, 2015) by the end of 2015</p> <p>very high probability achievable. This solution leaves the study with enough</p> <p>sample size to</p> <p>answering the primary hierarchically tested hypothesis and is also a good basis</p> <p>to evaluate the secondary endpoints (such as PFS, OS and molecular markers) in the</p> <p>Within a timely justifiable process.</p>
--------------	---

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/30388045>